Light-Based blood test may spot lung cancer early

NCT ID NCT07755020

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study is testing a new device called a nitride-based Raman biochip that analyzes blood samples using light to detect molecular patterns linked to lung cancer. Researchers will compare results from 2,000 people with lung cancer and 1,000 without to see if the test can accurately tell the two groups apart. The goal is to find a less invasive way to help diagnose and monitor lung cancer, potentially complementing current methods like CT scans and biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Nitride-based Raman biochip (a blood test device that analyzes molecular patterns)
What this could lead to
If successful, this could provide a simple blood test to help detect lung cancer earlier and monitor the disease over time, potentially reducing the need for invasive biopsies.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly change patient outcomes. The test's accuracy is still being evaluated, and it may not prove reliable enough for widespread clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Taichung Veterans General Hospital

    RECRUITING

    Taichung, 407219, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.